Adaptive Biotechnologies
David Goel is a seasoned finance professional with extensive experience in investment management. Since June 1999, David has served as Managing General Partner at Matrix Capital Management Company, L.P. In addition, David has been a Member of the Board of Directors at Adaptive Biotechnologies Corp. since August 2016, contributing to advancements in immune-based research. Prior to these roles, David held positions at Tiger Management as Associate Director, General Atlantic as Associate, and Morgan Stanley as Financial Analyst. David holds a Bachelor of Arts in Government (Magna Cum Laude) from Harvard University and graduated Cum Laude from Phillips Exeter Academy.
This person is not in any teams
This person is not in any offices
Adaptive Biotechnologies
17 followers
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision.